Add Formweb to your mobile device
Formulary synchronization in progress.
Please refer to Epic and your local
pharmacy
for available medications.
Search results for:
inotuzumab ozogamicin
inotuzumab ozogamicin
- Hazardous Drugs Rhazdrugs - Hazardous Drug Handling
- Provider restrictions: Restricted to hematology and oncology specialists
- Care Area restrictions: Restricted to outpatient use with financial approval or inpatient use for FDA approved indications
- Dose restrictions: Must maintain a minimum of 6 days between doses; may continue treatment for a maximum of up to 6 cycles for patients not proceeding to hematopoietic stem cell transplantation (HSCT)
Brand names: Besponsa
| Form | Strength |
|---|---|
| INJECTION, INTRAVENOUS | 0.9 mg |
Last updated: Aug. 7, 2024
Policies and procedures
Consults, protocols, and therapeutic interchanges
Additional information